Pomerantz Appointed Co-Lead Counsel in Humanigen Securities Litigation

On December 9, 2022, U.S. Magistrate Judge André M. Espinosa, of the District of New Jersey, appointed Pomerantz LLP as Co-Lead Counsel on behalf of its client, Joshua Mailey, who serves as the Co-Lead Plaintiff, and the class, in In re Humanigen, Inc. Sec. Litig., 22-cv-5258 (D.N.J.). This securities action alleges that Humanigen, Inc. misled the market regarding the regulatory and commercial prospects for lenzilumab – its lead product candidate an antibody treatment for cytokine storm (an auto-immune response triggered by infection that results in the overproduction of inflammatory proteins in the bloodstream). Humanigen is a clinical-stage biopharmaceutical company…